Clinical Efficacy and Effects on Serum Inflammatory Factors of Carbocisteine Combined with Budesonide in the Treatment of Asthma
- VernacularTitle:羧甲司坦联合布地奈德治疗哮喘的疗效及对血清炎症因子的影响
- Author:
Huiyan ZHANG
- Keywords:
Carbocisteine;
Budesonide;
Asthma;
Efficacy;
Serum inflammatory factors
- From:
China Pharmacist
2017;20(1):106-108
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the clinical efficacy and the effects on serum inflammatory factors of carbocisteine and budes-onide in the treatment of asthma. Methods:Totally 186 asthma patients were randomly divided into the observation group (93 cases) and the control group (93 cases). The control group received budesonide combined with the conventional treatment, the observation group was treated with carbocisteine and budesonide, and one week was a treatment course. The efficacy was observed. The airway re-sponsiveness and cough condition was respectively assessed by early respiratory resistance ( Rrsc) and Leicester cough questionnaire ( LCQ) . The improvement of day and night symptoms was observed, and the serum levels of inflammatory factors and the safety were also evaluated. Results:LCQ score of the observation group after the treatment was significantly higher than that of the control group, Rrsc score for day and night symptoms and serum IL-8, TNF-αand IgE levels were significantly lower than those in the control group, and the differences were statistically significant (P<0. 05). The effective rate of the observation group was 86. 02%, which was high-er than that of the control group (77. 42%), while the difference was not statistically significant (P>0. 05). The difference in the in-cidence of ADR between the groups was not statistically significant (P>0. 05). Conclusion: Carbocisteine and budesonide in the treatment of asthma can significantly improve asthma symptoms and reduce cough and inflammatory cytokines with promising safety.
